VOLITIONRX LTD (VNRX) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US9286612067
VOLITIONRX LTD financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 1.73 m USD |
| Operating income | -21.74 m USD |
| EBIT | -23.36 m USD |
| Net income | -23.36 m USD |
Full history since 2004, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About VOLITIONRX LTD
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient's cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is headquartered in Henderson, Nevada.
More stocks
- POWERCOMPUTE, INC. (PWCM)
- Vocodia Holdings Corp (VHAI)
- DarkPulse, Inc. (DPLS)
- Can B Corp (NASC)
- Onar Holding Corp (ONAR)
- Kairos Pharma, LTD. (KAPA)
- B-Scada, Inc. (SCDA)
- Hubilu Venture Corp (HBUV)
- AXIM BIOTECHNOLOGIES, INC. (AXIM)
- Dogecoin Cash, Inc. (DOGP)
- EHTI Eurasia High Technology Industries (LP2.DU)
- Bone Biologics Corp (BBLG)
Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.